Hematological Malignancies Drugs Market | Major Market Players are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hematological Malignancies Drugs Market Trends and Dynamics, Clinical Trial/Pipeline Analysis, Industry Competition Analysis, Revenue Forecast To 2031."

According to the latest market research, the global hematological malignancies drugs market is valued at US$ 13.76 Billion in 2021, and it is expected to reach US$ 42.78 Billion by 2031, with a CAGR of 13.7 % during the forecast period of 2023-2031.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1211

Hematological malignancies are the cancer types that affect the blood, bone marrow, and lymph nodes. Myeloma, leukemia, and lymphoma are the three types of hematological malignancies, and lymphoma is the most common blood cancer. Small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells are among the emerging targeted therapies that have improved clinical outcomes for blood malignancies.

The growth of the Hematological Malignancies Drugs Market can be attributed to factors, such as the rising prevalence of blood malignancies, rising healthcare expenditure, increasing R&D activities to develop novel cancer therapies, adoption of precision medicine in the field of hematological malignancies, increasing number of drug approvals for treating different types of hematological malignancies, growing innovations in leukemia and lymphoma targeted therapies. According to the Blood Cancer Statistics 2021, around 459,058 leukemia cases and more than 962,304 lymphoma cases are predicted to diagnose in the United States. Also, as per Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 Hodgkin (HL) and 77,240 Non-Hodgkin (NHL) Lymphoma cases. Thus, the rising incidences of leukemia, lymphoma cases are estimated to upsurge the demand for this market in the coming future.

However, the high cost of treatment and products, adverse effects of therapeutics, unfavourable medical reimbursement policies, and safety concerns are estimated to restrain the market expansion in the upcoming years.

Request for Sample and ToC: https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market--/1211

Regionally, North America is projected to generate the highest CAGR in this market over the forecast period due to the rising R&D activities in cancer research. The Asia Pacific region also majorly contributes to the growth of the Hematological Malignancies Drugs Market. The increasing cancer research funding, high prevalence of blood malignancies, and the rising need for effective therapies contribute to the market growth.

Major market players operating in the hematological malignancies drugs market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, among others.

Key developments in the market:
• In October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML) in two distinct indications.
• In September 2021, AbbVie and Genmab A/S published the results of the dose-escalation part of the Phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose-escalation and cohort expansion clinical trial eValueating the safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL).
• In March 2021, Sanofi SA received the US FDA approval for Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
• In August 2020, GlaxoSmithKline plc received US FDA approval for BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for patients with relapsed or refractory multiple myeloma.
• In July 2020, Takeda Pharmaceutical Co. Ltd. received US FDA approval for pevonedistat, an investigational cancer drug for treating higher-risk myelodysplastic syndromes.

Market Segments
Global Hematological Malignancies Drugs Market, by Drugs, 2023-2031 (Value US$ Mn)
• Monoclonal Antibodies
o Blincyto (Blinatumomab)
o Besponsa (Inotuzumab Ozogamicin)
o Lumoxiti (Moxetumomab Pasudotox)
o Mylotarg (Gemtuzumab Ozogamicin)
o Opdivo (Nivolumab)
o AiRuiKa (Camrelizumab)
o Tyvyt (Sintilimab)
o Tislelizumab
o Gazyva (Obinutuzumab)
o Zynlonta (Loncastuximab Tesirine-lpyl)
o Darzalex (Daratumumab)
o Blenrep (Belantamab Mafodotin-blmf)
o Keytruda (Pembrolizumab)
o Adcetris (Brentuximab Vedotin)
o Arzerra (Ofatumumab
• CAR-T Cell Therapy
o Tecartus (Brexucabtagene Autoleucel)
o Kymriah (Tisagenlecleucel)
o Yescarta (Axicabtagene Ciloleucel)
o Breyanzi (Lisocabtagene Maraleucel)
o Abecma (Idecabtagene Vicleucel)

Global Hematological Malignancies Drugs Market, by Pipeline Products, 2023-2031 (Value US$ Mn)
• Monoclonal Antibodies
o Teclistamab
o Iomab-B
o Ublituximab
o CS1001
• CAR-T Cell Therapy
o Ciltacabtagene Autoleucel (JNJ-68284528)

Global Hematological Malignancies Drugs Market, by Indications, 2023-2031 (Value US$ Mn)
• Leukemia
o Acute Lymphoblastic Leukemia
o Chronic Lymphoblastic Leukemia
o Acute Myeloid Leukemia
• Lymphoma
o Hodgkin's Lymphoma
o Non-Hodgkin's Lymphoma
• Multiple Myeloma

Global Hematological Malignancies Drugs Market, by region, 2023-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Hematological Malignancies Drugs Market, by Country, 2023-2031 (Value US$ Mn)
• The U.S.
• Canada

Europe Hematological Malignancies Drugs Market, by Country, 2023-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Hematological Malignancies Drugs Market, by Country, 2023-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Hematological Malignancies Drugs Market, by Country, 2023-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Hematological Malignancies Drugs Market, by Country, 2023-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of clinical trial/pipeline products for the global hematological malignancies drugs market
 To receive a market overview and future trends of the hematological malignancies drugs market
 To analyze the hematological malignancies drugs market drivers and challenges
 To get information on the Hematological Malignancies Drugs Market size (Value US$ Mn) forecast to 2030
 Major investments, mergers & acquisitions in the Hematological Malignancies Drugs Market industry

For More Information @ https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market--/1211

InsightAce Analytic Pvt. Ltd.
Asia: +91 79 72967118
Tel : +1 551 226 6109
Email: info@insightaceanalytic.com
Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.